Johns Hopkins has $65M to spend on taking their drugs right up to human studies
Researchers at Johns Hopkins University now have a new way to take a promising therapy to the threshold of Phase I, burnishing the value of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
